Vascular Dementia Pipeline Landscape Analysis: 12+ Key Players & 12+ Pipeline Drugs

DelveInsight's, "Vascular Dementia Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Vascular Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Vascular Dementia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Vascular Dementia Pipeline Report
• DelveInsight's Vascular Dementia Pipeline analysis depicts a robust space with 12+ active players working to develop 12+ pipeline treatment therapies.
• The leading Vascular Dementia Companies are working such as Merz Pharma, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharmaceutical, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company, Charsire Pharmaceutical, Cyclerion therapeutics, AriBio, DiaMedica Therapeutics, Suven Life Sciences, Guangzhou Magpie Pharmaceuticals, Resverlogix, ProNeurogen Therapeutics, Merz Pharma, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharmaceutical, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company, Charsire Pharmaceutical, Cyclerion therapeutics, AriBio, DiaMedica Therapeutics, Suven Life Sciences, Guangzhou Magpie Pharmaceuticals, Resverlogix, ProNeurogen Therapeutics, and others
• Promising Vascular Dementia Pipeline therapies such as donepezil, 0.9% Saline Solution, Prospecta, Rivastigmine, BAC treatment, Fufangdanshen Tablets, Akatinol Memantine 20 mg, Cilostazol, Aspirin, and others
• The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Dementia R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Dementia.

Request a sample and discover the recent advances in Vascular Dementia Treatment Landscape @ https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Vascular Dementia Overview

Vascular dementia (VaD) is one of the most common causes of dementia after Alzheimer's disease, causing around 15% of cases. Vascular dementia may result not only from large-vessel strokes (multi-infarct dementia) but also from ischemic lesions caused by small-vessel pathology, including lacunar strokes and incomplete white matter ischemia (subcortical ischemic vascular dementia), as well as from hypoperfusion caused by heart disease or circulatory disturbances. Cognitive changes in vascular dementia are much more variable than in other disorders such as Alzheimer's disease, and are highly dependent on the particular neural substrates affected by the vascular pathology.
Some symptoms may be similar to those of other types of dementia. Memory loss is common in the early stages of Alzheimer's, but is not usually the main early symptom of vascular dementia. Vascular dementia is caused by reduced blood supply to the brain due to diseased blood vessels. To be healthy and function properly, brain cells need a constant supply of blood to bring oxygen and nutrients. Blood is delivered to the brain through a network of vessels called the vascular system. If the vascular system within the brain becomes damaged - so that the blood vessels leak or become blocked - then blood cannot reach the brain cells and they will eventually die. There is currently no cure for vascular dementia: the brain damage that causes it cannot be reversed. However, there is a lot that can be done to enable someone to live well with the condition. This will involve drug and non-drug treatment, support and activities.

Recent Developmental Activities in the Vascular Dementia Market
• Sailuotong (SLT) capsule is a standardized three-herb preparation composed of ginseng, ginkgo, and saffron being evaluated for the treatment of vascular dementia in Phase III stage of development.
• Butylphthalide (NBP) is a compound found in Chinese celery seed extracts that can improve cognitive functions and may decrease Amyloid-beta levels in Alzheimer′s disease. NBP has antioxidant activities and may protect against oxidative/nitrosative stress, mitochondrial impairment and apoptosis. The drug is currently in Phase III stage of development for the treatment of patients with Vascular Dementia.
• Akatinol Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine is marketed for the treatment of moderate to severe Alzheimer's disease. Memantine works by blocking NMDA receptors, to which the neurotransmitter glutamate normally attaches. Neurotransmitters are chemicals in the nervous system that allow nerve cells to communicate with one another and overstimulation of the NMDA receptors can result in cell damage or death. The drug is in Phase III clinical development for the treatment of Vascular Dementia.

Vascular Dementia Emerging Drugs
• Akatinol Memantine: Merz Pharma
• Butylphthalide soft capsules: CSPC Ouyi Pharmaceutical
• SaiLuoTong: Shineway Pharmaceutical

Learn more about the emerging Vascular Dementia Clinical Trials @ https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Vascular Dementia Pipeline Therapeutic Analysis
There are approx. 12+ key companies which are developing the therapies for Vascular Dementia. The companies which have their Vascular Dementia drug candidates in the most advanced stage, i.e. phase III include, Merz Pharma.

Scope of the Vascular Dementia Pipeline Report
• Coverage- Global
• Vascular Dementia Therapeutic Assessment by Product Type
• Vascular Dementia Assessment by Stage and Product Type
• Vascular Dementia Assessment by Route of Administration
• Vascular Dementia Assessment by Stage and Route of Administration
• Vascular Dementia Assessment by Molecule Type
• Vascular Dementia Assessment by Stage and Molecule Type
• Vascular Dementia Companies- Merz Pharma, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharmaceutical, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company, Charsire Pharmaceutical, Cyclerion therapeutics, AriBio, DiaMedica Therapeutics, Suven Life Sciences, Guangzhou Magpie Pharmaceuticals, Resverlogix, ProNeurogen Therapeutics, Merz Pharma, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharmaceutical, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company, Charsire Pharmaceutical, Cyclerion therapeutics, AriBio, DiaMedica Therapeutics, Suven Life Sciences, Guangzhou Magpie Pharmaceuticals, Resverlogix, ProNeurogen Therapeutics, and others
• Vascular Dementia Pipeline Therapies- donepezil, 0.9% Saline Solution, Prospecta, Rivastigmine, BAC treatment, Fufangdanshen Tablets, Akatinol Memantine 20 mg, Cilostazol, Aspirin, and others

Table of content
1. Introduction
2. Executive Summary
3. Vascular Dementia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Vascular Dementia - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Vascular Dementia Collaboration Deals
9. Late Stage Products (Phase III)
10. Akatinol Memantine: Merz Pharma
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. CY6463: Cyclerion therapeutics
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I)
16. AR1001: AriBio
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Vascular Dementia Key Companies
20. Vascular Dementia Key Products
21. Vascular Dementia- Unmet Needs
22. Vascular Dementia- Market Drivers and Barriers
23. Vascular Dementia- Future Perspectives and Conclusion
24. Vascular Dementia Analyst Views
25. Vascular Dementia Key Companies
26. Appendix

Key Questions
Current Treatment Scenario and Emerging Therapies:-
• How many companies are developing Vascular Dementia drugs?
• How many Vascular Dementia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Dementia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vascular Dementia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vascular Dementia and their status?
• What are the key designations that have been granted to the emerging drugs?

For further information on the Vascular Dementia Pipeline Outlook Report @ https://www.delveinsight.com/report-store/vascular-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.